{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:21:43Z","timestamp":1790490103693,"version":"4.1.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2018\u201302532"],"award-info":[{"award-number":["2018\u201302532"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2017-00915"],"award-info":[{"award-number":["2017-00915"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["681712"],"award-info":[{"award-number":["681712"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["RDAPB-201809-2016615"],"award-info":[{"award-number":["RDAPB-201809-2016615"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016334","name":"Dementia Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Alzheimer Foundation","award":["AF-742881"],"award-info":[{"award-number":["AF-742881"]}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2017-0243"],"award-info":[{"award-number":["FO2017-0243"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A major concern of human immunodeficiency virus (HIV) dual therapy is a potentially lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal injury, and inflammatory biomarkers and dolutegravir (DTG) exposure in cerebrospinal fluid (CSF) in patients switching to DTG plus lamivudine (3TC). All participants maintained viral suppression in plasma and CSF at week 48. We observed no increase in CSF markers of inflammation or neuronal injury. Median (interquartile range) total and unbound DTG in CSF were 7.3 (5.9\u20138.4) and 1.7 (1.2\u20131.9) ng\/mL, respectively. DTG+3TC may maintain viral control without changes in inflammatory\/injury markers within the CNS reservoir.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa645","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T11:12:32Z","timestamp":1602069152000},"page":"1928-1933","source":"Crossref","is-referenced-by-count":12,"title":["No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV\/AIDS Research Network, PreEC\/RIS 62)"],"prefix":"10.1093","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-873X","authenticated-orcid":false,"given":"Juan M","family":"Tiraboschi","sequence":"first","affiliation":[{"name":"Bellvitge University Hospital. Bellvitge Biomedical Research Institute. University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhon","family":"Rojas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"UK Dementia Research Institute at UCL, London, United Kingdom"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Niubo","sequence":"additional","affiliation":[{"name":"Bellvitge University Hospital. Bellvitge Biomedical Research Institute. University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1532-5177","authenticated-orcid":false,"given":"Johanna","family":"Gostner","sequence":"additional","affiliation":[{"name":"Innsbruck Medical University, Innsbrusk, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Navarro-Alcaraz","sequence":"additional","affiliation":[{"name":"Bellvitge University Hospital. Bellvitge Biomedical Research Institute. University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Piatti","sequence":"additional","affiliation":[{"name":"Bellvitge University Hospital. Bellvitge Biomedical Research Institute. University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-9563","authenticated-orcid":false,"given":"Dietmar","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Innsbruck Medical University, Innsbrusk, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Rigo-Bonnin","sequence":"additional","affiliation":[{"name":"Pharmacology Service, Bellvitge University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[{"name":"Bellvitge University Hospital. Bellvitge Biomedical Research Institute. University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"2021060422094778100_CIT0001","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"2021060422094778100_CIT0002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12974-019-1404-9","article-title":"Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection","volume":"16","author":"Hermansson","year":"2019","journal-title":"J Neuroinflammation"},{"key":"2021060422094778100_CIT0003","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1212\/NXI.0000000000000512","article-title":"CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection","volume":"6","author":"Gissl\u00e9n","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021060422094778100_CIT0004","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/cid\/ciu477","article-title":"ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects","volume":"59","author":"Letendre","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021060422094778100_CIT0005","doi-asserted-by":"crossref","first-page":"ofz174","DOI":"10.1093\/ofid\/ofz174","article-title":"Dolutegravir cerebrospinal fluid diffusion in HIV-1-infected patients with central nervous system impairment","volume":"6","author":"Gel\u00e9","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021060422094778100_CIT0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13195-018-0339-1","article-title":"A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation","volume":"10","author":"Gaetani","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2021060422094778100_CIT0007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13195-018-0405-8","article-title":"Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup","volume":"10","author":"Woollacott","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2021060422094778100_CIT0008","author":"Center for Drug Evaluation and Research and Center for Veterinary Medicine, Food and Drug Administration, US Department of Health and Human Services."},{"key":"2021060422094778100_CIT0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021060422094778100_CIT0010","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO Study","author":"van Wyk","journal-title":"Clin Infect Dis"},{"key":"2021060422094778100_CIT0011","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/QAI.0000000000001863","article-title":"Genital HIV-1 shedding with dolutegravir (DTG) plus lamivudine (3TC) dual therapy","volume":"79","author":"Gianella","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021060422094778100_CIT0012","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jis326","article-title":"Central nervous system viral invasion and inflammation during acute HIV infection","volume":"206","author":"Valcour","year":"2012","journal-title":"J Infect Dis"},{"key":"2021060422094778100_CIT0013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/QAI.0b013e31815ace97","article-title":"Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy","volume":"47","author":"Yilmaz","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021060422094778100_CIT0014","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/QAD.0000000000002628","article-title":"Antiretroviral drug concentrations in brain tissue of adult decedents","volume":"34","author":"Ferrara","year":"2020","journal-title":"AIDS"},{"key":"2021060422094778100_CIT0015","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/jac\/dks517","article-title":"Etravirine in CSF is highly protein bound","volume":"68","author":"Nguyen","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021060422094778100_CIT0016","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/infdis\/jiz624","article-title":"Total and unbound bictegravir concentrations and viral suppression in cerebrospinal fluid of human immunodeficiency virus-infected patients (Spanish HIV\/AIDS Research Network, PreEC\/RIS 56)","volume":"221","author":"Tiraboschi","year":"2020","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa645\/34252830\/jiaa645.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/11\/1928\/38488457\/jiaa645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/11\/1928\/38488457\/jiaa645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:51:14Z","timestamp":1622850674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/11\/1928\/5922599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,13]]},"published-print":{"date-parts":[[2021,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa645","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,10,13]]}}}